Bli medlem
Bli medlem

Du är här


Nordic Nanovector: Nordic Nanovector ASA: Proposal from the Nomination Committee to the Annual General Meeting 19 May 2016

Date: 13.05.2016        Press Release no: 24/2016

Oslo, Norway, 13 May 2016

Reference is made to the notice published on 28 April 2016 regarding
the Annual General Meeting in Nordic Nanovector ASA (the "Company")
(OSE: NANO) to be held on 19 May 2016 at 10:00 am (CEST) at Thon
Hotel Vika Atrium in Munkedamsveien 45 in Oslo.

The proposal by the Nomination Committee referred to in items 7, 8, 9
and 10 of the notice is attached and available on the Company's

Due to the delayed publication of the proposal from the Nomination
Committee, the Company has decided that the deadline for submitting
the notice of attendance to the Annual General Meeting and/or the
power of attorney and prior voting is prolonged from 15 May 2016 at
16.00 (CEST) to 18 May 2016 at 12:00 (CEST).

For further information, please contact:

Tone Kvåle, Chief Financial Officer

Phone: +47 91 51 95 76


About Nordic Nanovector:

Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin®, the first in a new class of
Antibody-Radionclide-Conjugates (ARC) designed to improve upon a
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over
USD 12 billion by 2018. Betalutin® comprises a tumour-seeking
anti-CD37 antibody (HH1) conjugated to a low intensity radionclide
(lutetium-177). The preliminary data has shown promising efficacy and
safety profile in an ongoing Phase1/2 study in a difficult-to-treat
NHL patient population. The Company is aiming at developing
Betalutin® for the treatment of major types of NHL with first
regulator submission anticipated in 1H 2019. Nordic Nanovector
intends to retain marketing rights and to actively participate in the
commercialisation to Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The
Company is committed to developing its ARC pipeline to treat multiple
selected cancer indications. Further information about the Company
can be found at

This information is subject to duty of disclosure pursuant to Section
5-12 of the Norwegian Securities Trading Act.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.